Summary: Most attempts to model accurately [18FI_ DOPA imaging of the dopamine system are based on the assumptions that its main peripheral metabolite, 3-
In recent years, positron emission tomography (PET) has become an increasingly used tool to dem onstrate normal and abnormal brain functions in multiple neurological and neuropsychiatric disor ders. Apart from eSF]deoxyglucose and blood flow agents, considerable interest has been given to the investigation of tracers selective for the dopaminer gic (DA) system. Numerous clinical and pharmaco logical studies have shown that abnormalities in this selective 18F regional accumulation in brain was apparent in normal or lesioned animals. The plasma metabolite analysis revealed that only the negatively charged metab olites (e.g., sulfated conjugates) that do not cross the blood-brain barrier were found in significant quantities in the plasma. A one-compartment, three-parameter model was adequate to describe the kinetics of [ l BF]3 _ OM-DOPA. In conclusion, assumptions concerning neurotransmitter system are involved in disorders of mood and locomotion. One of the tracers that has received the most attention is 6-esF]L-3,4-fluoro dihydroxyphenylalanine (e8F]DOPA).
6-[18F]DOPA represents an excellent marker of DA presynaptic activity (Firnau et aI., 1987; Cum ming et a!., 1988) . This tracer is an analogue of the natural amino acid phenylalanine and can be decar boxylated selectively within DA terminals through the activity of dopa decarboxylase (DDC) (Hefti et a!., 1981) . Accumulation of 1 8F in the striatum ap pears to be correlated to the concentrations of en dogenous striatal DA, the activity of DDC, and the integrity of DA nigrostriatal neurons (Garnett et aI., 1983; Chiueh et aI., 1986) . The ratios of 18F accu mulation in DA-rich areas such as striatum to 1 8F accumulation in DA-poor areas such as cerebellum or occipital cortex bear some relationship to the DA striatal levels as well as to the cerebrospinal fluid concentrations of homo vanillic acid (HV A), the main DA metabolite in the primate (Caine et aI., 1985; Nahmias et aI., 1985; Leenders et aI., 1986; Guttman et a!., 1988; Doudet et a!., 1989) . How ever, these data provide only qualitative informa tion. A precise physiological interpretation of the [,sF]DOPA PET studies and a better understanding of DA function require the development of a quan titative model based on brain and plasma data. Such a model is still unavailable (Firnau et a!., 1987; Gar nett et a!., 1980) . Its development requires a greater understanding of [l s F]DOPA metabolites in the plasma, their time course, and their peripheral and central fate.
The metabolism of L-DOPA, either cold or la beled with 14C, 3H, or 18F, has been studied in ro dent, human, and nonhuman primates (Wooten and Horne, 1982; Garnett et aI., 1983; Horne et a!., 1984; Boyes et a!., 1986; Chiueh et a!., 1986; Cum ming et a!., 1987; Firnau et a!., 1987 Firnau et a!., , 1988 . Periph erally, through the activity of liver DDC in partic ular, [, s F] DOPA is rapidly metabolized to labeled DA and its sulfated form, followed later by the me tabolites, i.e., 6-[ I s F]3-methoxytyramine, 6-[ 18F]_ HVA, and 6-[' s F]3,4-dihydroxyphenylacetic acid (DOPAC). In addition to decarboxylation, [,sF]DOPA is also methylated by cathechol O-methyltransferase, forming 3-0-methyl-6-[I s F] L-4-h ydrox yphe n y lalanine ([ 1 8F] 3-OM-DOPA). In the brain, after administration of radioactively labeled DOPA, striatal radioactivity is mainly composed of labeled DA and 3-0M-DOPA. HVA and DOPAC make only small contributions (Wooten and Horne, 1982; Garnett et a!., 1983; Fir nau et a!., 1987) .
Most peripheral metabolites of L-DOPA do not cross the blood-brain barrier (BBB). Its main me tabolite, the amino acid 3-0M-DOPA, has, how ever, been reported to readily cross the BBB using the large neutral amino acid (LNAA) transport sys tem in humans (Firnau et a!., 1988) and rat (Horne et a!., 1984; Wade and Katzman, 1975) , where a uniform distribution of this compound throughout the brain has been reported. Therefore, accounting for [' s F]3-0M-DOPA behavior during [, s F]DOPA PET studies is a critical factor in the design of a mathematical model. Indeed, because [, s F]3-OM-DOPA crosses the BBB, it represents a second input function to the brain (Firnau et a!., 1988) . This factor must be taken into consideration for accurate modeling of the DA system based on [,8F]DOPA injection. A number of groups have assumed the distribution of ['8F]3-0M-DOPA to be homogenous and have corrected striatal 18F values for this input using posterior cortical areas or cerebellar areas as the control (see, for example, Martin et a!., 1989) . Little information, however, is available in primates concerning 3-0M-DOPA behavior. This is important since large species differences in the metabo lism of DA have been documented (Merits et a!., 1973; Wang et a!., 1983) .
The generally accepted assumptions concerning 3-0M-DOPA are that peripherally metabolized 3-0M-DOPA (a) crosses the BBB but (b) as in rodents has a uniform distribution and only behaves as a homogenous background throughout the brain, (c) has an identical distribution in normal subjects or in subjects with known DA abnormalities [i.e., for in stance, in I-methyl-4-phenyl-l,2,3,6-tetra hydropyridine (MPTP)-treated monkeys or in par kinsonian patients], and (d) is not converted to [18F]DOPA in significant quantities. To test some of these assumptions, 18F-labeled 3-0M-DOPA was synthesized and injected into rhesus monkeys. Fol lowing injection of ['8F]3-0M-DOPA, PET scans were obtained over a 3 h period to assess brain radioactivity. Simultaneously, plasma radioactivity and metabolite analyses were performed.
METHODS

Animal procedures
Five rhesus monkeys (Macaca mulatta), matched for age, size, and sex, were included in this study. They were housed and fed under identical conditions. All animals had previously received a PET scan using [18FjDOPA in the year preceding the C8Fj3-0M-DOPA study.
Three of these animals were normal controls. One mon key had received i. v. MPTP injections 33 months before the study (3 x 0. 5 mg/kg at I week intervals and then 0.5 mg/kg 40 days later). A fifth animal received MPTP in jections into the right internal carotid artery, 25 months prior to the PET study (2 x 0. 75 mg/kg at 3 week inter vals). In both cases, MPTP HCI was dissolved in saline and sterilized by filtration through a 0.22 j.Lm pore filter. Acutely, the two animals were affected and displayed ri gidity and akinesia as well as loss of facial expression and vocalization. They gradually recovered over 4-8 weeks. At the time of the PET study, the i. v. treated animal was evaluated as clinically normal in comparison to the con trols, by outside investigators unaware of their prior treatment. The contralateral side of the hemilesioned an imal stabilized in a mildly affected stage. Compared to the right ipsilateral side, the left side remained slightly rigid and underused. This animal also spontaneously rotated toward the ipsilateral side (�70--80 turns/h).
Anesthesia procedures, monitoring, and preparation of the animal for a PET study have been described in detail in a previous report (Doudet et a!. , 1989) . The monkey was first immobilized with ketamine hydrochloride (10 mg/kg i. m. ) and then anesthetized with low doses of so dium pentobarbital (10--20 mg/kg i. v. ) before placement of an arterial catheter in the femoral artery. The monkey was positioned in the scanner in the horizontal stereo taxic plane, as determined by the infraorbital ridge and the external auditory meatus. A thermoplastic mask molded over the animal's face helped prevent head mo tion. Additional low doses of sodium pentobarbital were given as needed (30--4 0 mg/h). PET tracers were injected through the right saphenous vein and arterial blood sam ples collected from the left femoral artery.
Radiopharmaceutical synthesis of [
18 F]3-0M-DOPA Thirty five milligrams of L-methy-N-acetyl-[�-(3-methoxy-4-acetoxy)Jalaninate was dissolved in 20 ml of glacial acetic acid. Fluorine-18-labeled acetyl hypofluo rite produced by an on-line method from the cyclotron gas target mixture of 0.4% elemental fluorine in neon (Jewett et aI., 1984) was bubbled through the solution at a flow rate of SO mUmin. Following the fluorination reac tion, the acetic acid solvent was evaporated and 3 ml of 4 N hydrochloric acid solvent was added to the residual solid material. This solution was refluxed at 120°C for 20 min, followed by solvent evaporation and two successive water wash evaporation in vacuo. The residue was dis solved in O.S ml of phosphate buffer (pH 7.0).
The 3-0-methyl-6-[IBFJfluoro-L-DOPA was separated from starting materials and other fluorinated chemical products by preparative reverse phase (ODS-3, 10 fLm, 10
x SO mm, Whatman, Inc.) high-pressure liquid chroma tography (HPLC) using a solvent consisting of S% CH3CN/9S% (1 % aqueous acetic acid) at a flow rate of 3.8 ml/min. The product had a retention time of 16.S min under these conditions. Following isolation of the crude product, the mobile phase was evaporated and reconsti tuted in I % acetic acid-physiologic saline with terminal sterilization by filtration.
The chemical and radiochemical purity of the resultant product was determined utilizing several HPLC systems and several standards. The radiochemical purity averaged greater than 9S%.
We utilized two analytical HPLC systems for the de termination of chemical and radiochemical purity of the final formulation. One unit consisted of a C-18 reverse phase column (S fLm, 4.6 x 200 mm, Alltech) with mobile phase per liter of 0.1 g of Na 2 EDT A, 1.2S g of heptane sulfonic acid, S ml of triethylamine, IS ml of acetonitrile, and S ml of 8S% phosphoric acid adjusted to pH 2.3. A flow rate of 1 mllmin was used. The mass detection sys tem consisted of an amperometric electrochemical detec tor (BAS, LC4B, West Lafayette, Inc.) and fractional radioactivity assay (Chen et aI., 1989) . The second sys tem utilized a previously reported analytical separation scheme (Eisenhofer et aI., 1986) but an ultraviolet detec tor (Gilson 116) operated at 26S nm. A radiation detector (Beckman, Model 170) was coupled to the effluent of the mass detector.
The identification of the [IBF]3-0M-DOPA was con firmed using a gas chromatograph interfaced with a se lective mass detector. The samples were derivatized us ing trifluoroethanol and pentafluoropropionic anhydride. The molecular ion for eBF]3-0M-DOPA was present at mlz 603. Other prominent ions in the spectra were as follows: mlz 119, 301, 440, and 603. These ions are con sistent with the assigned structure.
Scanning technique
The positron emission tomograph used for the [ IBF]3 _ OM-DOPA studies was the same as for the prior [ I BF]DOPA studies, a Scanditronix PC1024-7B. This brain scanner allows simultaneous acquisition of data for seven slices (13.8 mm interval) with reconstructed image resolution of 6 mm full width at half-maximum and an axial resolution of 11-12 mm. The scanning procedures
were the same as for the [ I BF]DOPA studies and have been described elsewhere (Doudet et aI., 1989) . Briefly, to provide an accurate identification of the basal ganglia when no IBF accumulation was visually detectable in any transaxial slice, a blood flow study using 1 50-labeled wa ter (10 mCi) was performed. The I SO-labeled water data were rapidly reconstructed on line and the visualization of the basal ganglia in at least one of the slices verified. This position in the scanner determined the level ZO of [IBF]3-0M-DOPA data acquisition.
A blank and four transmission scans were obtained prior to injection of the ligand for attenuation correction.
[IBF]3-0M-DOPA (2.0-3.7 mCi) diluted in 3-S ml of saline was injected over a I min period. Scanning began at the time of isotope injection. One minute scans were obtained during the first 10 min followed by a succession of 10 min scans until the end. Scan data were obtained at level ZO over 180 min. Between 90 and 180 min, scanning at three additional levels also for 10 min each, interleaved with scanning at the ZO level, permitted the acquisition of typ ically 10-12 overlapping slices containing the brain and surrounding structures with an interslice interval of ap proximately 3.S mm.
Plasma and metabolite analysis
Arterial blood samples (O.S to 1 ml) were drawn at the same time points as in the CBF]DOPA studies. Samples were obtained every 20-30 s during the first S min, every 2-S min during the following IS min, every 10 min until 60 min, and every 30 min thereafter. Samples were saved in heparinized tube immediately placed on ice and then cen trifuged for 2 min. The total 18F activity curve was ob tained from 100-300 fLl of plasma counted in a well gamma counter calibrated with the scanner. Remaining plasma from samples taken at 2, 4, 6, 8, 10, 12, IS, 20, 40, 60, 90, 120 , ISO, and 180 min were processed to obtain the levels of [18F]3-0M-DOPA and its possible metabolites. The metabolite analysis technique was the same as for eBF]DOPA. Metabolite analysis divided plasma radioac tivity into four components: [ 1 8F]DOPA, [ l BF]3 _ OM-DOPA, and anion and cation metabolites. Briefly, negatively and positively charged metabolites were sep arated by passage of a 0.1 or 0.2 ml aliquot of plasma through a cation/anion exchange column at pH S.S. The column effluent was then extracted with alumina at pH 8.7 to isolate [lBFJ3-0M-DOPA and the possible [ l BF]DOPA. Metabolite data were expressed as the per centage of total plasma activity. Metabolite analysis pro cedures are described in detail elsewhere (McLellan et aI., 1991) .
Data analysis
Data analysis was performed using the same technique as previously described (Doudet et aI., 1989) . The 1 B p concentration in identified areas was obtained from cir cular regions of interest (ROIs) of 21 pixels each (pixel size of 4 mm 2 , ROI area of 0.84 cm 2 ). The ROIs were placed on the striatal areas of the eBpJ3-0M-DOPA im ages using a method of identification independent of in vestigator subjectivity. As described in a previous paper (Doudet et aI., 1989) , ROIs were placed on the striatal areas of the ZO level blood flow pictures, and then were automatically relocated by the computer to the corre sponding slice of the [18 p J3-0M-DOPA images of the ki netic set. Other ROls were positioned around known DA-poor areas located on the slice directly below the striatal slice at the level of the cerebellum and the temporal cor tices; on the striatal slice at the level of the occipital, temporal, temporoparietal, parietal, and occipitoparietal cortices, the latter in a position similar to the one used as a background region in the [ 1 8F]DOPA studies; and on the slice directly above the striatal slice at the level of the parietal cortex. As controls, two external ROls were po sitioned on the prominent temporal muscles surrounding the monkey's head.
The coordinates of these ROls were then used to pro duce time-activity curves (TACs) from each ROI for each monkey. Brain and blood data were normalized to the amount of mCi injected. The T AC of the ratios of 1 8F accumulation in the striatum to 1 8F accumulation in each cortical area was calculated for each animal to assess the possible relationship between DA activity and [ 1 8F]3 _ OM-DOPA accumulation. Furthermore, to be able to compare data between animals, or to compare brain data with plasma data, all brain, plasma, and metabolite activ ity curves were interpolated at standard predefined times (computed linear interpolation) and compared using re peated-measures analysis of variance. These T ACs were then averaged and a mean curve computed for striatum, each cortical area, muscle, striatum/cortical area ratio, plasma, and percentage of metabolites over time.
Compartment modeling
A model consisting of one tissue compartment plus vas cular radioactivity was used to fit the tissue T ACs for the ROIs. Three parameters were estimated, i.e., the influx rate constant K I (mlimin/ml), the effiux rate constant k 2 (min -I ), and the blood volume Vb (mliml) , using the equation
where Cj is the ROI concentration value for scan i (nCi/ cc), tj is the end of scan i, Cp' is the total plasma radio activity (nCi/cc), Cp is the plasma radioactivity after cor rection for metabolites (nCi/ccL and (9 is the convolution operator. The term K 1 exp( -k 2 t) (9 Cp(t) is the predicted concen tration of [ 1 8F]3-0M-DOPA in the single tissue compart ment within each ROI. The model assumes that no me tabolites cross the BBB. The term VbCp'(t) is the esti mated vascular radioactivity component in the ROl. This term assumes that the arterial plasma concentration is representative of the blood in the brain ROI. The leading integration in the equation accounts for the time averag ing of each PET scan interval. Parameter estimates were determined by iterative weighted least-squares fit. The weights were chosen as the inverse of the ROI variance, which was approximated from the total counts in each scan, the decay correction factor, and the length of the scan. The equilibrium distribution volume Ve = K/k 2 (ml/m\) was also calculated. K I
and Ve values are ex pressed per ml of brain because PET measures nCi/cc instead of nCi/g. Data from one animal were not analyzed due to technical difficulties in acquiring plasma data.
RESULTS
eSF]3-0M-DOPA rapidly crossed the BBB and entered the brain. No selective regional IsF accumulation was apparent in any brain areas in any of the five animals studied in the 10-12 transaxial slices. This absence of selective accumulation was not due to mispositioning of the monkey in the scan ner or error in placement of the ROls as striatal areas were clearly visualized in the same animal on matching slices either with eSF]DOPA in a previous study (Fig. 1) or with I50-labeled water for blood flow during the same session (Fig. 2) T ACs for striatal, cortical, and cerebellar ROls are presented in Fig. 3 . For clarity of illustration, data from a single cortical area equivalent to the one used as a background region in the eSF]DOPA stud ies are used in all graphs. No differences were fo und between left and right sides of the brain, even in the hemilesioned monkey. By repeated-measures analysis of variance, no significant differences were found between cortical, striatal, or cerebellar IsF activity (p = 0. 264). Furthermore, the cerebellar, striatal, and cortical IsF accumulations did not ap pear to differ between the normals and the two MPTP-treated monkeys (Fig. 3) .
The ratios of striatum to cortical and cerebellar areas in the eSF]3-0M-DOPA studies were similar in all animals, even though large differences existed in these same animals using eSF]DOPA (Fig. 4) . For each animal, the ratio of striatum to cortical and cerebellar areas between 30 and 180 min showed very little fluctuation and very little variance be tween animals (0.96 to 1. 25 depending on the ROI location, mean of 1. 16 ± 0. 15). This ratio reached a plateau around 30 min and remained stable over the course of the study (Fig. 4) . As expected, a greater accumulation of I8F activity was found for muscle than for brain or plasma (Fig. 3) , the muscle being one of the main storage areas for 3-0M-DOPA in the rat (Rose et aI. , 1988) . IsF activity in the muscle also remained stable over the course of the study (Fig. 3) .
Plasma blood curves were nearly superimpos able. Brain T ACs compared to plasma T ACs showed no significant difference in the clearance of IsF activity (Fig. 5) , except during the early time points (0 to 30 min), where plasma activity re mained much higher than in brain. This phenome non, however, was expected, as entrance of [ l sF]3 _ OM-DOPA into the brain is probably via the LNAA transport system of the BBB.
No difference was apparent in the respective fr action of metabolites between normal and MPTP treated animals. The percentage of [lsF]3-0M DOPA remained very high (>87%) over the course of the study. The only significant fraction of metab olites extracted was composed of negatively charged metabolites, i.e., the acidic metabolites and sulfated conjugates (Fig. 6) .
The one-compartment, three-parameter model provided a good fit to the tissue concentration data (Fig. 7) . The parameter estimates are shown in Ta ble 1 and show a homogenous pattern throughout the brain. Mean K J values ranged between 0.03 and 0.05 ml/min/ml and the equilibrium distribution vol ume ranged from 0.8 and 1.0 mllml. Paired compar isons between regions did demonstrate some signif icant differences between regional values (e.g., be tween basal ganglia and occipitoparietal cortex) although the magnitude of these differences was not large. The variability across animals of the esti mates was moderate, ranging between 10 and 20% for KJ in all regions and 5 to 15% for Ve' DISCUSSION Overall, our findings are consistent with those previously obtained in other species (Rivera Calimlin, 1974; Wade and Katzman, 1975; Rose et J Cereb Blood Flow Metab, Vol. ll, No.5, 1991 aI., 1988). In primates as well as in the other species studied, 3-0M-DOPA is readily transported into the brain. In this study, plasma and brain l sF values came into apparent equilibrium by 30 min.
Similarly, following the administration of [ l sF]3 _ OM-DOPA, the distribution of J SF activity through out the brain appeared to be uniform, i.e., without region-specific accumulation. The l sF accumulation was independent of an intact DA nigrostriatal sys tem. No difference in 18F distribution was apparent between normal controls and animals with various degrees of nigrostriatal lesions or between left and right sides of the brain in hemilesioned animals. This suggests that there is no significant trapping of eSF]3-0M-DOPA in the striatum or other brain ar eas. These findings make it very unlikely that eSF]3-0M-DOPA undergoes further metabolism in the brain, in particular to eSF]DOPA, contrary to what earlier reports suggested (Rivera-Calimlin, 1974) .
The three-parameter model used to describe the kinetics of eSF]3-0M-DOPA in all brain regions is composed of a single tissue compartment plus vas- cular radioactivity. In order to determine if this model is sufficient to describe the measured data, the three-parameter model fits were compared to fits from a four-parameter, two-compartment model. This four-parameter model included an ad ditional parameter k3 that represented the rate of irreversible incorporation of tissue eSF]3-0M DOPA. Of 36 regional curves analyzed (nine each in four animals), 15 regions showed a statistically sig nificant improvement with a four-parameter model compared to the three-parameter model (F test, p < 0.05). However, the estimated k3 values in these regions were small with a large variability (mean of 0. 00 15 ± 0. 00 14 min -I ) compared to the tissue clearance constant k2 (mean of 0. 044 ± 0. 006 min -I). In addition, there was no pattern in the regions that showed statistically significant k3 val ues. This small effect could easily be due to small scanner quantitation errors (e. g. , scatter correc tion). Therefore, it appears that a model with a sin gle tissue compartment is adequate to describe [18F]3-0M-DOPA kinetics.
This one-compartment approach could be used as part of a complete kinetic model for the uptake and retention of eSF]DOPA and its metabolites. Small differences in uptake and distribution volume of eSF]3-0M-DOPA between subcortical and poste rior cortical regions were found in this analysis. These differences should be carefully considered if a region with low eSF]DOPA uptake is used in the analysis of DA-rich area kinetic curves. Similarly, the ratios of striatum to most nonspecific areas (posterior cortices) were not equal to 1 but were slightly higher. These differences did not appear to be related to an actual striatal accumulation as (a) tissue ratio, K 1 , and Ve values were similar in nor mal and MPTP-treated animals and (b) striatal and cortical 18F accumulation was not significantly dif ferent. It is likely that differences in partial volume averaging due to differences in mixtures of gray matter with white matter and extracranial tissues may account for much or all of the differences found between regional values. Indeed, in mon keys, due to the brain size and the resolution of the scanner, partial volume averaging is likely to be very different for striatum (a round, thick structure) than cortical areas (thin, band-shaped structure). Indeed, all of our ROIs were circular and of the same size. In support of this assumption, the ratio of basal ganglia to cerebellum (also a thick, wide structure) was found to be consistently equal to 1 in all animals (mean of 1.023 ± 0.089). Cerebellar and striatal ROls are mainly composed of gray matter. Cortical area ROls in the monkey contain an un known amount of white matter and CSF, most likely larger than in the striatum, accounting for the lower l8F accumulation values obtained in cortical ROls compared to striatal and cerebellar ROls. The Kl, k2' and distribution volume values found in this study are somewhat different from the cal culated estimates reported by Reith et al. (1990) The only significant fraction of metabolites extracted was composed of ,8F anion, i.e., mainly sulfated conjugates.
higher KI values may derive from species and/or methodology differences (for example, amino acid concentration in the plasma).
The recently reported K I , k2' and distribution vol umes for the synthetic amino acid [' I C] aminocy c1ohexanecarboxylate (ACHC) (Koeppe et aI. , 1990) are in good agreement with our own data us ing [' s F]3-0M-DOPA. Indeed, it is likely that 3-0M-DOPA, like ACHC, is not incorporated into protein. ACHC is transported through the BBB by the same LN AA carrier as other natural amino acid such as 3-0M-DOPA. Kinetic constants for the two tracers would be expected to have similar depen dencies upon transporter concentrations and plas ma and tissue concentrations of amino acids. How ever, slightly different affinities and/or V ma x of the two substrates for the carrier, varying competitive inhibition due to different plasma and tissue con centrations of amino acid (our animals were fasted for at least 12 h before a scan), species differences, etc. are likely to be responsible for the differences found. Furthermore, small differences between dis tribution volume in subcortical and cortical regions are also reported by these authors (Koeppe et al. ,1990) in humans using ACHC as the tracer. The metabolite data suggest that [' s F]3-0M DOPA is not converted into [, s F]DOPA at any point during the 3 h following its administration. How ever, we cannot rule out that small quantities of [l s F]DOPA are produced as earlier studies sug gested (Rivera-Calimlin, 1974 ). In such instance, the quantities of [, s F]DOPA would have had to have been extremely small to have eluded our abil ity to detect its selective striatal accumulation and its presence in the plasma.
The modeling of [ l s F]DOPA experiments is based on assumptions concerning [' s F]3-0M-DOPA's be havior in brain. From these data, it appears accept able to subtract the nonspecific activity from a cer ebellar or cortical area from the total activity in striatal areas to obtain the specific activity when performing graphical analysis with [, s F]DOPA. Al ternatively, a single tissue compartment is adequate to describe [' s F]3-0M-DOPA kinetics in a compart ment model. This study also points out the impor tance of the position of the nonspecific area chosen. As demonstrated here, slight differences in the ra tios of specific/nonspecific areas exist, likely due to partial voluming error, emphasizing the importance 
